1. P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB. (23rd June 2022) Authors: Nakamura, R.; Hendricks, R.; Dokhaei, R.; Susilo, M.; Wilson, D.; Trudel, S.; Cohen, A.; Harrison, S. J.; Krishnan, A.; Fonseca, R.; Adamkewicz, J. I.; Li, M.; Wong, C.; Cooper, J.; Sumiyoshi, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 852 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗